Open AccessEffective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B 3
Author(s) -
Khan Nahid A,
Auranen Mari,
Paetau Ilse,
Pirinen Eija,
Euro Liliya,
Forsström Saara,
Pasila Lotta,
Velagapudi Vidya,
Carroll Christopher J,
Auwerx Johan,
Suomalainen Anu
Publication year - 2014
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.1002/emmm.201403943
Subject(s) - mitochondrial biogenesis , nad+ kinase , mitochondrion , sirt3 , biology , mitochondrial myopathy , mitochondrial disease , sirtuin , nicotinamide adenine dinucleotide , microbiology and biotechnology , mitochondrial dna , myopathy , respiratory chain , biochemistry , genetics , enzyme , gene
Nutrient availability is the major regulator of life and reproduction, and a complex cellular signaling network has evolved to adapt organisms to fasting. These sensor pathways monitor cellular energy metabolism, especially mitochondrial ATP production and NAD + / NADH ratio, as major signals for nutritional state. We hypothesized that these signals would be modified by mitochondrial respiratory chain disease, because of inefficient NADH utilization and ATP production. Oral administration of nicotinamide riboside ( NR ), a vitamin B3 and NAD + precursor, was previously shown to boost NAD + levels in mice and to induce mitochondrial biogenesis. Here, we treated mitochondrial myopathy mice with NR . This vitamin effectively delayed early‐ and late‐stage disease progression, by robustly inducing mitochondrial biogenesis in skeletal muscle and brown adipose tissue, preventing mitochondrial ultrastructure abnormalities and mt DNA deletion formation. NR further stimulated mitochondrial unfolded protein response, suggesting its protective role in mitochondrial disease. These results indicate that NR and strategies boosting NAD + levels are a promising treatment strategy for mitochondrial myopathy.